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In this study, novel hexa coordinated ruthenium(III) complex of the type Na[RuCl2L2)] (where L = monobasic 
bidentate Schiff base derived from the condensation of 5-nitrosalicyladehyde with aniline) has been synthesized and 
characterized by electrospray ionization time-of-flight mass spectrometry, infrared spectroscopy and 
ultraviolet/visible spectrophotometry. Schiff base N-phenyl-5-nitrosalicylideneimine is coordinated to the ruthenium 
via imine nitrogen and phenolic oxygen. Mass spectra showed molecular ion (M-) at m/z 653.9641 which 
corresponds to [C26H18Cl2N4O6Ru]-. The in vitro antimicrobial properties of the Schiff base and the complex were 
tested by micro-dilution technique and agar plate assay for determination of minimum inhibitory concentration 
(MIC) and minimum bactericidal concentration (MBC). The compounds showed a higher antibacterial activity 
against tested Gram-positive bacteria (Staphylococcus aureus ATCC 33591 and ATCC 29213), whereas against the 
Gram-negative bacteria (Pseudomonas aeruginosa ATCC 27853, Escherichia coli ATCC 25922, Klebsiella 
pneumoniae ATCC 700603) were ineffective. The genotoxic effects of Ru(III) complex were investigated using the 
Cytokinesis Block Micronucleus (CBMN) assay in human lymphocytes cultures. The cell culture treated with the 
complex at a concentration of 3.7 µg/mL exhibit the most prominent effect of decreasing the frequency of 
micronucleus for 44%, while at the concentrations of 1.5 and 7.4 µg/mL effect is slightly lower (40%), compared to 
the control cell culture.  
Keywords: Ruthenium(III) complex, N-phenyl-5-nitrosalicylideneimine, Minimum inhibitory concentration, 
Minimum bactericidal concentration, Cytokinesis block micronucleus assay 
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INTRODUCTION 
Over the past few decades, metal complexes containing Schiff bases have attracted a significant attention 
in coordination chemistry. The reasons for this lies in Schiff base ligands as a result of their ability to 
stabilize numerous different metals in a variety of oxidation states, simple preparation, stability, structural 
diversity as well as a wide range of applications.1-5 A huge number of Schiff base metal complexes have 
been synthesized and extensively studied in a broad diversity of fields as biochemical, antitumor and 
antimicrobial agents.6-11 The azomethine linkage of the Schiff bases is crucial for its biological activity. 
Among the Schiff base metal complexes, ruthenium complexes have been broadly explored and their 
therapeutic potentials have been the subject of intensive research during the last decades.12 They are 
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reported to have antitumor, antiviral, antifungal, antibacterial, antioxidant activity.13-16 Ruthenium(III) 
Schiff base complexes exhibited better antibacterial activity than their ligands, Schiff bases, against 
Esherichia coli, Bacillus subtilis, Staphylococcus aureus.15,11 The biological activity of the potential drug 
in the pre-clinical investigations should be comprehensively examined with the aim to obtain as much 
information as possible about its therapeutic and side effects in the living organism.17,18 In the last decade, 
there is a remarkable increase of bacterial pathogens that present multidrug resistance than currently 
available antimicrobial agents. Therefore, the development of new antimicrobial strategies and 
antibacterial agents is an active area of research.19,20 A relatively small number of complexes containing 
Schiff base derived from 5-nitrosalicylaldehyde is stored in the Cambridge Structural Database (CSD).21 
The syntheses of ruthenium(III) Schiff base complexes are in focus of interest because of their wide range 
of applications.22 Besides the estimation of antimicrobial activity of new complex compounds as potential 
therapeutic agents, the detection and the evaluation of genotoxic effects are of vital importance. 
According to our knowledge, genotoxic activities of metal complexes have been very little described by 
using cytokinesis block micronucleus (CBMN) assay in human lymphocytes. The genotoxic activities of 
copper(II), cadmium(II) and lead(II) complexes with macrocyclic ligands have been described by Beynek 
and others, while organometallic compounds of tin(II) and tin(IV) by Damati and others.23,24 In our 
previous paper, we studied in vitro effects of the Ru(III) thiosemicarbazone complexes on human 
lymphocytes using the CBMN assay.18 The CBMN assay in peripheral human lymphocytes is well 
established cytogenetic technique and is developed to score micronuclei (MN) in different nucleated cell 
types in vitro or in vivo.25,26 The analysis of micronuclei (MN) in cultured lymphocytes is frequently used 
as a preferred method to biomonitor human exposure to genotoxic agents. Micronuclei are cytoplasmatic 
chromatin masses that occurred like small nuclei as a result of lesions/adducts at the level of DNA or 
chromosomes, or at the level of proteins directly or indirectly involved in chromosome segregation (e.g. 
tubulin). The CBMN assay allows micronuclei that have completed one nuclear division to be specifically 
scored in binucleated cells after blocking cytokinesis by addition of cytochalasin B (Cyt B) during the 
targeted mitosis.27 Cyt B allows karyokinesis (a division of the cell nucleus) but also is an inhibitor of the 
mitotic spindle that prevents cell division (cytokinesis).28 The simplicity, rapidity, sensitivity and 
versatility of the in vitro micronucleus test in different cell types make it a valuable tool for genotoxicity 
screening.24 In view of the wide interest in the chemistry of ruthenium, the present article is a continuation 
of our research activities on the synthesis, characterization and biological properties of the new 
ruthenium(III) Schiff base complex.   
EXPERIMENTAL 
Materials and methods  
The chemicals used in this study were all of the analytical grade purity and were used as received. The 
infrared spectra were acquired using KBr disc technique on Perkin Elmer Spectrum BX FTIR System 
over the range 4000 – 400 cm-1. The electronic absorption spectra of the samples were measured in 
dichloromethane solution using Perkin Elmer UV/Visible lambda 35 spectrophotometers in the range of 
200 – 700 nm. The mass spectra of the complex were recorded using Agilent 6210 Time-of-Flight LC/MS 
system (Agilent Technologies, Santa Clara, California, USA) via an electro spray ionization (ESI) 
interface (ESI–ToF–MS). Nitrogen was used as drying gas (12 L/min) and nebulizing gas at 350°C (45 
psi). The OCT RF and capillary voltage were set to 250 V and 4.0 kV, respectively. The voltages applied 
to the fragmentor and skimmers were 140 V and 60 V, respectively. Scanning was performed from 100 to 
2000 m/z (mass-to-charge ratio). The compound was dissolved in the acetonitrile (concentration of 1 
mg/mL), and a direct injection of 5 µL sample was conducted by 1200 Series HPLC (Agilent 
Technologies, Waldbronn, Germany) without a separation column, using isocratic mobile phase: 50% 
acetonitrile and 50% of 0.2% formic acid in water (v/v) at flow rate: 0.2 ml/min.  
 
Synthesis of the Schiff base, L 
The Schiff base, N-phenyl-5-nitrosalicylideneimine, hereinafter L, was prepared by adding an ethanolic 
solution of 5-nitrosalicylaldehide (4 mmol; 0.6685 g) to an ethanolic solution of aniline (4 mmol; 365 
µL). The mixture was refluxed for one hour at 65°C. The precipitated crystals were recrystallized from 
hot ethanol and then dried under vacuum. The purity was checked by IR spectroscopy.  
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Synthesis of Ru(III) Complex, Na[RuCl2L2)] 
The amount of 0.484 g (2 mmol) L in 20 mL of ethanol was added to the solution of 0.262 g RuCl3·3H2O 
(1 mmol) in 10 mL of ethanol and refluxed for three hours at 70°C. The resulting solution was reduced to 
about 15 mL by rotary vacuum evaporation. After the solution was left overnight aqueous solution (1 mL) 
NaCl (0.117 g; 2 mmol) was added to precipitate the complex. The dark green partly crystalline 
compound was filtered off, washed with ethanol and ether, and dried in vacuum.  
Na[RuCl2L2] 
ESI-ToF MS m/z: [C26H18Cl2N4O6Ru]- 653.9641; FT-IR L (KBr, cm-1): 1621 s [νs(C=N)], 1290 s [νs(C-




Antimicrobial activity was tested on pathogens collected from the Unit of Clinical Microbiology of the 
Clinical Centre University of Sarajevo. The in vitro antimicrobial activities of the ligand and Ru(III) 
complex were tested by micro-dilution technique and agar plate assay for determination of minimum 
inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) according to the 
literature procedure.29,30 Complex and ligand were dissolved in 97% dimethyl sulfoxide (DMSO) to a 
stock concentration of 20 mg/mL and then diluted into the initial concentration of 512 µg/mL in sterile 
Tryptic Soy Broth. Serial two-fold dilutions of decreasing concentration starting with 256 µg/mL and 
ending with 0.25 µg/mL of compounds were obtained by pipetting 50 µL of the compound solution in 
sterile 96-well microtiter plates with 50 µL of broth in each well. Antimicrobial susceptibility testing was 
performed against referral strains of Gram-positive bacteria Staphylococcus aureus ATCC 33591 and 
ATCC 29213 and Gram-negative bacteria Pseudomonas aeruginosa ATCC 27853, Escherichia coli 
ATCC 25922 and Klebsiella pneumoniae ATCC 700603. An inoculum of each bacterial strain was made 
up to a turbidity equivalent of 0.5 McFarland standard prior to testing from colonies of a pure strain 
culture. The volume of 50 µL inoculum was dispensed in each well containing 50 µL of broth and diluted 
compound. Final volume per well was 100 µL. The same testing was performed with positive controls 
containing Gentamycin and Vancomycin instead of studied compounds. Inoculated compound-free broth 
with diluents was used as a negative control. After primary incubation at 35-37°C for 22 hours, MIC 
results were read. The MIC endpoint was the lowest concentration of antibiotic/compound that did not 
exhibit visible microorganism growth. After MIC test has been completed, subculturing on selective and 
differential agar plate from all dilutions with no visible bacterial growth was done. The first dilution 
without bacterial growth observed on plate represented MBC. For Staphylococcus strains, subculturing 
was done to mannitol-salt agar (MSA), while for other strains, MacConkey agar plates were used, both 
not containing the test compounds. After incubation at 35-37°C for 22 hours, MBC results were recorded 
in cfu/mL. 
 
Cytokinesis-Block Micronucleus (CBMN) Assay, Statistics and Index Calculation 
The experiments were performed on peripheral blood lymphocytes obtained from five healthy non-
smoking female volunteers not undergoing any drugs or other substances treatment. The volunteers were 
aware of this study that was conducted according to the code of ethics of the World Medical Association 
(Helsinki Declaration of 1964, as revised in 2002)31 and gave permission for using their blood for this 
experiment. Two 5-mL aliquots of blood were collected from each volunteer and stored in heparinised 
sterile tubes (Becton Dickinson, Bradford, MA). The blood samples were obtained at the Medical Unit 
concerning a safety protocol blood/borne pathogen/biohazard according to current Health and Ethical 
regulations in Serbia, Law on Health Care.32 The culture lymphocytes were treated with the complex. 
Three concentrations of the complex were used, i.e. 1.5 µg/mL, 3.7 µg/mL and 7.4 µg/mL, and it was not 
added to the one cell culture which was used as the control. As a positive control Amifostine WR-2721 
(98%, S-2[3-aminopropylamino]-ethylphosphothioic acid, Marligen-Biosciences, USA) at concentration 
of 1.0 µg/mL was used. They were added to the cultures 25 h after phytohaemagglutinin (PHA) 
stimulation and life until harvest and incubated in a thermostat at 37°C. After treatment with the tested 
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complex for 19 h, all cultures were rinsed with a pure medium, transferred into 5 mL fresh RPMI 1640 
medium (RPMI 1640 Medium + GlutaMAX + 25 mM HEPES; Invitrogen-Gibco-BRL, Vienna, Austria) 
and incubated for additional 72 h. Circa 2 × 106 blood lymphocytes were set up in 5 mL RPMI-1640 
medium supplemented with 15% of calf serum and 2.4 µg/mL of phytohaemaglutinin (Invitrogen-Gibco-
BRL). Three concentrations of the tested complex were added to the samples one hour after initiating the 
cell stimulation. The incidence of spontaneously occurring MN in control samples was scored. For MN 
preparation, the cytokinesis-block micronucleus assay was performed as previously described.33,34 At least 
1000 binucleated (BN) cells per sample were scored, registering MN according to the literature 
criteria.33,35 After 44 h of culture, 6 µg/mL of cytochalasin B (Invitrogen-Gibco-BRL, Vienna, Austria) 
was poured into each sample and allowed to incubate another 24 h. After 72 h of culture, the cells were 
washed with 0.9% NaCl (Merck, Sharp and Dohme GMBH, Vienna, Austria), collected by centrifugation 
and treated with a hypotonic solution (56% KCl + 0.9% NaCl mixed in equal volumes) at 37°C. The cell 
suspension was prefixed in methanol/acetic acid in a ratio of 3:1, washed three times with fixative, and 
dropped onto a clean slide.30 The slides were air dried and stained with alkaline Giemsa 2% (Sigma-
Aldrich, Vienna, Austria). At least 1000 binucleated (BN) cells per sample were scored, registering MN 
according to the criteria described in the literature.33,35 In order to determine possible cytotoxic effects, the 
cytokinesis-block proliferation index (CBPI) was calculated as suggested by Surralles and others.36 CBPI 
is given by the equation: CBPI = [(M1 + 2M2 + 3(M3 + M4)]/N, where M 1-4 represent the numbers of 
cells with one, two, three and four nuclei, respectively, and N is the total number of cells scored. For the 
analysis of MN, only binucleated cells with well-preserved cytoplasm were scored (under a light 
microscope with a 40 × 10 magnification) by following the criteria given in the HUMAN project website 
(http://www.humn.org).33 The number of binucleated cells with 1, 2, 3 or more MN was then tabulated. 
The data for each treatment were expressed as the frequency of MN per 1000 binucleated cells. The 
statistical analysis of the obtained data was conducted with the use of the Origin software package version 
7.0. The statistical significance of the difference between the data pairs was evaluated by analysis of 
variance (One way ANOVA) followed by the Tukey test. In all experiments, we considered p < 0.01 and 
p < 0.05 to indicate statistical significance.  The index calculating is presented as the % of change 
comparing different groups. 
RESULTS AND DISCUSSION 
Synthesis and Spectral Characterization  
The Schiff base ligand was synthesized according to the general literature procedure by condensing 5-
nitrosalicyladehyde and aniline. Schiff base, L react with RuCl3 in 2:1 molar ratio in absolute ethanol to 
afford stable ruthenium(III) complex, sodium dichlorobis[N-phenyl-5-nitrosalicylideneiminato-
N,O]ruthenate(III), hereinafter Na[RuCl2L2] (Fig.-1). Novel ruthenium(III) bis-Schiff base anionic 
complex derived from 5-nitrosalicylaldehyde and aniline is stable in the air, soluble in most common 
polar organic solvents and insoluble in non-polar organic solvents and water.  
 
Fig.-1: Preparation Scheme for Na[RuCl2L2] 
 
The Schiff base ligand has been characterized by infrared and electronic spectroscopy, while the complex 
has been characterized by mass spectrometry, UV/Vis and infrared spectroscopy. The high-resolution 
mass spectrum of the complex was recorded in the negative ESI ionization mode, where the anionic 
component was detected as [C26H18Cl2N4O6Ru]- with m/z (100%): 653.9641. The characteristic infrared 
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frequencies and electronic spectral data of ligand and complex are listed in Table-1. A strong band in the 
free ligand observed at 1621 cm-1 is the characteristic of the azomethine (-HC=N) group. After 
coordination of the nitrogen to the ruthenium, this band is shifted to 1603 cm-1. This shift toward lower 
frequency for 18 cm-1 indicating the coordination of ligand via azomethine nitrogen, while electron 
density in the azomethine group is reduced.2 An intense band at 1290 cm-1 in the free ligand assigned to 
phenolic C-O group has shifted to higher frequency (1313 cm-1) after complexation what it proves that the 
phenolic group coordinates to ruthenium atom after deprotonation. Coordination of the ligand with the 
ruthenium as the metal center was further substantiated by the appearance of two new weak bands at 543 
and 487 cm-1 which could be assigned to ν(Ru-N) and ν(Ru-O), respectively. The electronic spectra of the 
ligand and Ru(III) complex were recorded in dichloromethane in the range 700 – 220 nm. The electronic 
spectrum of the free Schiff base display absorption bands within the range 230-350 nm due to pi→pi*, 
n→pi* and intraligand transitions.11 The Ru(III) complex shows three bands. The absorption bands below 
360 nm are ligand-centered (π→π* and n→π*) transitions.2,11 The weak broad band centered at 625 nm 
have been assigned to the d→d transition of the Ru(III) ion (2T2g→2A2g) which is in agreement with 
assignments made for similar ruthenium(III) complexes.22 The nature of the electronic spectrum supports 
an octahedral geometry of the Ru(III) ion in the complex.   
Table-1: Characteristic IR (cm-1) and Electronic (nm) Bands of the Ligand and its Complex 
Ligand/Complex ν(C=N-H) ν(C-OH) ν(Ru-N) ν(Ru-O) λ 
cm-1 cm-1 cm-1 cm-1 nm 
L 1621 1290 - - 232, 270, 350 
Na[RuCl2L2] 1603 1313 543 487 245, 351, 625 
 
Antimicrobial Activity 
The results of antimicrobial activity were compared to the corresponding positive controls. The Ru(III) 
complex showed equally high antibacterial activity (MIC 16 µg/mL) in tested Gram-positive bacteria S. 
aureus ATCC 29213 (MSSA) and ATCC 33591 (MRSA). Subsequently, the ligand demonstrated higher 
values of MICs then complex, differing in one or two double dilutions (Table-2). However, their 
antibacterial activity was lower in comparison to the positive controls. Against the Gram-negative 
bacteria (P. aeruginosa ATCC 27853, E. coli ATCC 25922 and K. pneumoniae ATCC 700603), both 
complex and ligand were ineffective, starting with their initial dilution of 256 µg/mL (Table-2). MBC 
confirmed the MIC results for each tested compound and bacterial strain.  
 
Table-2: Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) of Tested 
Na[RuCl2L2] and L 
Referral strain  
Na[RuCl2L2] L Gentamycin Vancomycin* 
MIC MBC MIC MBC MIC MBC MIC MBC 
(µg/mL) (µg/mL) (µg/mL) (µg/mL) 
Staphylococcus aureus 
ATCC 29213 (MSSA) 16 16 32 32 4 4 4 4 
Staphylcoccus aureus 
ATCC 33591 (MRSA) 16 16 64 64 8 8 4 4 
Escherichia coli 
ATCC 25922 256 256 256 256 4 4 / / 
Klebsiella pneumoniae 
ATCC 700603 256 256 256 256 8 8 / / 
Pseudomonas aeruginosa 
ATCC 27853 256 256 256 256 2 2 / / 
*Vancomycin is not the therapy of choice for Gram-negative bacteria and was not tested on them during the 
study.  
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The Results of Cytokinesis-Block Micronucleus Assay  
The synthesized Ru(III) complex was tested for in vitro protective effect on chromosome aberrations in 
peripheral human lymphocytes using the cytochalasin-B blocked micronucleus (MN) assay at 
concentrations of 1.5, 3.7 and 7.4 µg/mL. The frequencies and distribution of MN in human lymphocytes 
were scored, and the results are given in Table-3. Amifostin (WR-2721), a phosphorylated aminothiol 
pro-drug, which is an analog of cysteamine, was used as a positive control.37 The cell cultures treated with 
amifostine at concentrations of 1.0 µg/mL led to a decrease of 18% in the MN frequency compared to 
control cell cultures. The most prominent effect (p < 0.01) of decreasing the frequency of MN by 44%, 
when compared with the control cell cultures, exhibited the cell cultures treated with the tested 
Na[RuCl2L2] at a concentration of 3.7 µg/mL. The concentrations of 1.5 and 7.4 µg/mL of this complex, 
exhibited decreasing the significant (p < 0.01), frequency of MN by 40%, when compared with the 
control cell cultures.  
 
Table-3: Incidence of  MN, Cytokinesis-Block Proliferation Index, Distribution MN per cells and Frequency of 
















Control 24.00 ± 1.82 1.91 ± 0.17
 
1.26 ± 0.05 1.64 ± 0.03 100.00 % 
Amifostin 19.69 ± 0.85 1.56 ± 0.10
 
1.27 ± 0.05 1.97 ± 0.03 82.04 % 
(1.0 µg/mL) 
Na[RuCl2L2] 
14.34 ± 0.99 a,b 1.34 ± 0.06 1.09 ± 0.01 1.69 ± 0.05 59.8 % (1.5 µg/mL) 
Na[RuCl2L2] 
13.38 ± 1.89 a,b 1.24 ± 0.13 1.07 ± 0.05 1.56 ± 0.05 55.8 % (3.7 µg/mL) 
Na[RuCl2L2] 
14.53 ± 1.41 a,b* 1.21 ± 0.14 1.21 ± 0.06 1.75 ± 0.08 60.5 % (7.4 µg/mL) 
 
MN/1000 Bn cells - incidence of micronuclei in 1000 binucleated cells; % Bn cells witch micronuclei; 
MN/Bn cells - the incidence of micronuclei in binucleated cells; CBPI- cytokinesis-block proliferation 
index; Frequency of MN: incidence of MN presented as % from control groups in cell cultures of human 
lymphocytes treated with different concentration of complex. The statistical significance of the difference 
between the data pairs was evaluated by analysis of variance (One-way ANOVA) followed by the Tukey 
test. Statistically, the difference was considered significant at p<0. Compared with control groups, 
statistically significant difference p < 0.01. 
b Compared with amifostine – WR 2721, statistically significant difference p < 0.01. 
b* Compared with amifostine – WR 2721, statistically significant difference p < 0.05. 
 
For the determination of the effect of the tested complex on cell proliferation, cytokinesis-block 
proliferation index (CBPI) was used. The mean CBPI values and standard errors calculated at different 
concentrations of the complex were presented in Table-3. Complex CPBI and Amifostin value are 
comparable and suggested an inhibitory effect on lymphocyte proliferation of tested Na[RuCl2L2]. In this 
study, we found that the lower concentration of the complex has a favorable effect on lymphocyte cells 
culture by decreasing the frequency of MN. Our results afford the indication of protective effects of the 
tested complex on cytogenetic and damages in human lymphocytes treated in vitro. 
 
CONCLUSION 
The anionic complex compound of Ru(III) with N-phenyl-5-nitrosalicylideneimine was synthesized. It 
was found that ligand acts as an anionic bidentate O,N-donor ligand which is coordinated to the 
ruthenium through azomethine nitrogen and phenolic oxygen. The evidence for that was detected by 
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analyzing shifts of imines nitrogen toward lower frequency and ones of phenolic oxygen to a higher 
frequency in the IR spectra of the synthesized complex. The assumed formula of molecular ion 
[C26H18CL2N4O6Ru]-, was confirmed in the mass spectrum of the complex, m/z: 653.9641. For Gram-
positive bacteria (S. aureus ATCC 33591 and ATCC 29213), the antibacterial activity of the complex was 
higher than the one of the ligands alone, whereas against the Gram-negative bacteria (P. aeruginosa 
ATCC 27853, E. coli ATCC 25922 and K. pneumoniae ATCC 700603) studied compounds were 
ineffective. MBC confirmed the MIC results for each tested compound and bacterial strain. Also, the 
antioxidant potential of Ru(III) complex in peripheral human lymphocytes by using CMBN assay was 
tested. The cell culture treated with the complex at a concentration of 3.7 µg/mL exhibit the most 
prominent effect of decreasing the frequency of micronucleus for 44%, while at the concentrations of 1.5 
and 7.4 µg/mL effect is slightly lower (40%), compared to the control cell culture. Synthetic protectors, 
such as Amifostin WR-2721, used in the treatment of humans, decrease the frequency of MN by about 
18%.38 The results of this study are essential given Amifostin. 
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